Business Description
Monte Rosa Therapeutics Inc
NAICS : 541714
SIC : 2834
ISIN : US61225M1027
Total Employee Number:
161Description
Monte Rosa Therapeutics Inc is a clinical-stage biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. The company has three programs in clinical development: MRT-6160, a VAV1-directed MGD for immune-mediated diseases; MRT-8102, a NEK7-directed MGD for inflammatory diseases driven by IL-6, and the NLRP3 inflammasome; and MRT-2359, a GSPT1-directed MGD for metastatic castration resistant prostate cancer (mCRPC).
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 17.06 | |||||
Equity-to-Asset | 0.71 | |||||
Debt-to-Equity | 0.08 | |||||
Debt-to-EBITDA | -0.28 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 3/9 | |||||
Altman Z-Score | 4.36 | |||||
Beneish M-Score | 5.83 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 37.9 | |||||
3-Year EPS without NRI Growth Rate | 40.8 | |||||
3-Year FCF Growth Rate | 47.1 | |||||
3-Year Book Growth Rate | -13.5 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | -60.9 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | -42.58 |
Momentum Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 85.85 | |||||
9-Day RSI | 73.71 | |||||
14-Day RSI | 65.95 | |||||
3-1 Month Momentum % | 25.15 | |||||
6-1 Month Momentum % | 14.14 | |||||
12-1 Month Momentum % | 305.39 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 9.54 | |||||
Quick Ratio | 9.54 | |||||
Cash Ratio | 9.38 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -9.9 | |||||
Shareholder Yield % | -18.35 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Operating Margin % | -345.21 | |||||
Net Margin % | -302.69 | |||||
EBITDA Margin % | -325.8 | |||||
FCF Margin % | -45.76 | |||||
OCF Margin % | -34.17 | |||||
ROE % | -42.1 | |||||
ROA % | -27.11 | |||||
ROIC % | -147.78 | |||||
3-Year ROIIC % | 287.66 | |||||
ROC (Joel Greenblatt) % | -278.23 | |||||
ROCE % | -35.31 | |||||
Moat Score | 5 | |||||
Tariff Resilience Score | 7 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 41.57 | |||||
PB Ratio | 3.44 | |||||
Price-to-Tangible-Book | 3.44 | |||||
EV-to-EBIT | -7.89 | |||||
EV-to-Forward-EBIT | 1.83 | |||||
EV-to-EBITDA | -8.36 | |||||
EV-to-Forward-EBITDA | 1.68 | |||||
EV-to-Revenue | 27.23 | |||||
EV-to-Forward-Revenue | 29.7 | |||||
EV-to-FCF | -59.51 | |||||
| Price-to-Net-Current-Asset-Value | 3.89 | |||||
| Price-to-Net-Cash | 3.99 | |||||
Earnings Yield (Greenblatt) % | -12.67 | |||||
FCF Yield % | -1.09 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:GLUE
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Monte Rosa Therapeutics Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 42.953 | ||
| EPS (TTM) ($) | -1.634 | ||
| Beta | 2.1153 | ||
| 3-Year Sharpe Ratio | 0.69 | ||
| 3-Year Sortino Ratio | 1.59 | ||
| Volatility % | 94.95 | ||
| 14-Day RSI | 65.95 | ||
| 14-Day ATR ($) | 1.278201 | ||
| 20-Day SMA ($) | 18.18275 | ||
| 12-1 Month Momentum % | 305.39 | ||
| 52-Week Range ($) | 4.12 - 25.77 | ||
| Shares Outstanding (Mil) | 84.48 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Monte Rosa Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Monte Rosa Therapeutics Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-06 | In 135 days | ||
| Second quarter earnings results for 2026 | 2026-08-07 | In 44 days | ||
| General meeting for 2026 | 2026-06-11 08:30 | 16.52 (+0.79%) | ||
| Jefferies Global Healthcare Conference in New York | 2026-06-04 11:40 | 17.59 (-1.24%) | ||
| TD Cowen 7th Annual Oncology Innovation Summit (virtual) | 2026-05-27 12:00 | 19.20 (+0.52%) | ||
| First quarter earnings results for 2026 | 2026-05-07 | 20.39 (+5.05%) | ||
| Annual report for 2025 | 2026-03-17 | 16.35 (-1.45%) | ||
| Fourth quarter earnings results for 2025 | 2026-03-17 | 16.35 (-1.45%) | ||
| Barclays 28th Annual Global Healthcare Conference | 2026-03-10 12:30 | 17.66 (+1.67%) | ||
| TD Cowen 46th Annual Health Care Conference | 2026-03-02 15:10 | 17.75 (-1.83%) |
Show
Entries
Monte Rosa Therapeutics Inc Frequently Asked Questions
What is Monte Rosa Therapeutics Inc(GLUE)'s stock price today?
The current price of GLUE is $21.27. The 52 week high of GLUE is $25.77 and 52 week low is $4.12.
When is next earnings date of Monte Rosa Therapeutics Inc(GLUE)?
The next earnings date of Monte Rosa Therapeutics Inc(GLUE) is 2026-08-07 Est..
Does Monte Rosa Therapeutics Inc(GLUE) pay dividends? If so, how much?
Monte Rosa Therapeutics Inc(GLUE) does not pay dividend.
Guru Commentaries on NAS:GLUE
No articles.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on Monte Rosa Therapeutics Inc
No articles.
Headlines
See More- 1
Jun 11, 2026
Kymera, Monte Rosa among gainers as Novartis inks deal for molecular glue drugs
Seeking Alpha • 1:36pm
- 1
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers